PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.06
0.06 - 0.24
8.7K / 3.59M (Avg.)
-1.55 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.58%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
46.64%
Positive gross profit growth while CRN.AX is negative. John Neff would see a clear operational edge over the competitor.
191.76%
EBIT growth above 1.5x CRN.AX's 19.60%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
90.24%
Positive operating income growth while CRN.AX is negative. John Neff might view this as a competitive edge in operations.
153.85%
Net income growth above 1.5x CRN.AX's 47.33%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
154.17%
EPS growth above 1.5x CRN.AX's 47.22%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
154.17%
Diluted EPS growth above 1.5x CRN.AX's 47.31%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.57%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.57%
Reduced diluted shares while CRN.AX is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
169.21%
OCF growth under 50% of CRN.AX's 11374.81%. Michael Burry might suspect questionable revenue recognition or rising costs.
133.22%
FCF growth 1.25-1.5x CRN.AX's 113.93%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
No Data
No Data available this quarter, please select a different quarter.
-56.59%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-72.78%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
117.39%
OCF/share CAGR of 117.39% while CRN.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
144.23%
Positive OCF/share growth while CRN.AX is negative. John Neff might see a comparative advantage in operational cash viability.
-87.51%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
101.21%
10Y net income/share CAGR of 101.21% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
119.90%
Positive 5Y CAGR while CRN.AX is negative. John Neff might view this as a strong mid-term relative advantage.
-94.42%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-55.05%
Negative equity/share CAGR over 10 years while CRN.AX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
62.39%
Positive 5Y equity/share CAGR while CRN.AX is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
525.13%
Positive short-term equity growth while CRN.AX is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
2.37%
Dividend/share CAGR of 2.37% while CRN.AX is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
82.91%
We show growth while CRN.AX is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-5.14%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-1.07%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-2.47%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
12.63%
We expand SG&A while CRN.AX cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.